Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
MAPK in Cancers: From Signalling Pathways to Therapeutic Targets
share announcement

MAPK in Cancers: From Signalling Pathways to Therapeutic Targets

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 13967

Special Issue Editor

Dr. Duarte Pignatelli

E-Mail Website
Guest Editor
1.Cancer Signalling & Metabolism, Instituto de Investigação e Inovação em Saúde (I3S), Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Universidade do Porto, 4200‐135 Porto, Portugal
2.Department of Endocrinology, Centro Hospitalar Universitario S João, (S Joao University Hospital Center) 4200‐135 Porto, Portugal.
Interests: adrenal cortex carcinoma; adrenal tumors; Cushing’s syndrome; incidentalomas; pheocromocytomas

Special Issue Information

Dear Colleagues,

The mitogen-activated protein kinase (MAPK) is an evolutionary-conserved signaling cascade that plays a crucial role in cell signal transduction in response to a range of extracellular and intracellular stimuli, both in physiological and pathological conditions.

The MAPK/ERK pathway is the best studied of the mammalian MAPK pathways, and it is dysregulated in a large number of human cancers. This pathway has many diverse effects in the regulation of oncogenesis, tumor progression, differentiation, and apoptosis. Significant efforts have led to the clinical success of some MAPK-ERK pathway inhibitors. However, the clinical benefits of these inhibitors are frequently compromised by the development of drug resistance.

In this Special Issue, we will publish reviews and original research that provide new insights into the MAPK/ERK signaling pathway in cancers, how it can be targeted therapeutically, and how it is possible to overcome the already observed drug resistance.

Dr. Duarte Pignatelli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • MAPK/ERK pathway
  • Human cancers
  • MAPK/ERK pathway component mutations
  • MAPK/ERK pathway-targeted therapies
  • Drug resistance
  • Combination therapy
  • MAPK/ERK pathway enrollment in tumor metabolic reprogramming

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

19 pages, 806 KiB  
Review
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
by Hyuk Moon and Simon Weonsang Ro
Cancers 2021, 13(12), 3026; https://doi.org/10.3390/cancers13123026 - 17 Jun 2021
Cited by 109 | Viewed by 9969
Abstract
Hepatocellular carcinoma (HCC) is a major health concern worldwide, and its incidence is increasing steadily. Recently, the MAPK/ERK signaling pathway in HCC has gained renewed attention from basic and clinical researchers. The MAPK/ERK signaling pathway is activated in more than 50% of human [...] Read more.
Hepatocellular carcinoma (HCC) is a major health concern worldwide, and its incidence is increasing steadily. Recently, the MAPK/ERK signaling pathway in HCC has gained renewed attention from basic and clinical researchers. The MAPK/ERK signaling pathway is activated in more than 50% of human HCC cases; however, activating mutations in RAS and RAF genes are rarely found in HCC, which are major genetic events leading to the activation of the MAPK/ERK signaling pathway in other cancers. This suggests that there is an alternative mechanism behind the activation of the signaling pathway in HCC. Here, we will review recent advances in understanding the cellular and molecular mechanisms involved in the activation of the MAPK/ERK signaling pathway and discuss potential therapeutic strategies targeting the signaling pathway in the context of HCC. Full article
(This article belongs to the Special Issue MAPK in Cancers: From Signalling Pathways to Therapeutic Targets)
►▼ Show Figures

Figure 1

13 pages, 964 KiB  
Review
JNK in Tumor Microenvironment: Present Findings and Challenges in Clinical Translation
by Shing Yau Tam and Helen Ka-Wai Law
Cancers 2021, 13(9), 2196; https://doi.org/10.3390/cancers13092196 - 3 May 2021
Cited by 21 | Viewed by 2857
Abstract
The c-Jun N-terminal kinases (JNKs) are a group of mitogen-activated protein kinases (MAPKs). JNK is mainly activated under stressful conditions or by inflammatory cytokines and has multiple downstream targets for mediating cell proliferation, differentiation, survival, apoptosis, and immune responses. JNK has been demonstrated [...] Read more.
The c-Jun N-terminal kinases (JNKs) are a group of mitogen-activated protein kinases (MAPKs). JNK is mainly activated under stressful conditions or by inflammatory cytokines and has multiple downstream targets for mediating cell proliferation, differentiation, survival, apoptosis, and immune responses. JNK has been demonstrated to have both tumor promoting and tumor suppressing roles in different cancers depending on the focused pathway in each study. JNK also plays complex roles in the heterogeneous tumor microenvironment (TME). JNK is involved in different tumorigenesis pathways. TME closely relates with tumor development and consists of various stressful and chronic inflammatory conditions along with different cell populations, in which the JNK pathway may have various mediating roles. In this review, we aim to summarize the present knowledge of JNK-mediated processes in TME, including hypoxia, reactive oxygen species, inflammation, immune responses, angiogenesis, as well as the regulation of various cell populations within TME. This review also suggests future research directions for translating JNK modulation in pre-clinical findings to clinical benefits. Full article
(This article belongs to the Special Issue MAPK in Cancers: From Signalling Pathways to Therapeutic Targets)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop